Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Myeloma research: the next 10 years

Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, shares his views on the next steps for multiple myeloma research, highlighting the need to optimize when therapy is commenced, identify the best combination approaches, incorporate measurable residual disease (MRD), and the potential benefits and optimal use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.